Royalty Pharma (RPRX)
(Delayed Data from NSDQ)
$28.26 USD
+0.54 (1.95%)
Updated Sep 16, 2024 04:00 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Balance Sheet
Fiscal Year End for Royalty Pharma PLC falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 495 | 1,736 | 2,189 | 2,062 | 341 |
Receivables | 37 | 37 | 68 | 39 | 39 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 742 | 782 | 621 | 596 | 453 |
Total Current Assets | 1,274 | 2,555 | 2,878 | 2,697 | 832 |
Net Property & Equipment | 14,089 | 13,493 | 13,718 | 12,368 | 10,842 |
Investments & Advances | 1,012 | 736 | 910 | 903 | 678 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 6 | 29 | 52 |
Deposits & Other Assets | 7 | 30 | 4 | 23 | 46 |
Total Assets | 16,382 | 16,813 | 17,516 | 16,020 | 12,450 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 15 | 8 | 6 | 11 | 11 |
Current Portion Long-Term Debt | 0 | 998 | 0 | 0 | 291 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 52 | 54 | 58 | 152 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 95 | 107 | 108 | 145 | 31 |
Total Current Liabilities | 161 | 1,167 | 171 | 308 | 333 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 6,135 | 6,119 | 7,096 | 5,817 | 5,975 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 3 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6,298 | 7,288 | 7,267 | 6,124 | 6,308 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 4,011 | 3,666 | 3,508 | 2,866 | 0 |
Retained Earnings | 2,518 | 1,965 | 2,255 | 1,921 | 2,825 |
Other Equity | 3,558 | 3,897 | 4,488 | 5,111 | 3,320 |
Treasury Stock | 3 | 3 | 3 | 2 | 4 |
Total Shareholder's Equity | 10,084 | 9,525 | 10,249 | 9,896 | 6,141 |
Total Liabilities & Shareholder's Equity | 16,382 | 16,813 | 17,516 | 16,020 | 12,450 |
Total Common Equity | 10,084 | 9,525 | 10,249 | 9,896 | 6,141 |
Shares Outstanding | 597.40 | 607.20 | 607.10 | 607.10 | NA |
Book Value Per Share | 16.88 | 15.69 | 16.88 | 16.30 | -0.06 |
Fiscal Year End for Royalty Pharma PLC falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,803 | 872 | 495 | 942 | 2,178 |
Receivables | 24 | 22 | 37 | 38 | 35 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 752 | 665 | 742 | 749 | 740 |
Total Current Assets | 2,579 | 1,560 | 1,274 | 1,729 | 2,954 |
Net Property & Equipment | 13,890 | 13,465 | 14,089 | 13,230 | 13,268 |
Investments & Advances | 1,160 | 1,101 | 1,012 | 876 | 871 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 28 | 4 | 7 | 20 | 29 |
Total Assets | 17,657 | 16,131 | 16,382 | 15,856 | 17,121 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 23 | 12 | 15 | 14 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 999 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 56 | 13 | 52 | 13 | 54 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 196 | 100 | 95 | 102 | 113 |
Total Current Liabilities | 276 | 125 | 161 | 128 | 1,172 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 7,602 | 6,139 | 6,135 | 6,131 | 6,127 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 27 | 1 | 11 | 9 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 7,905 | 6,267 | 6,298 | 6,270 | 7,308 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 4,101 | 4,075 | 4,011 | 4,007 | 4,031 |
Retained Earnings | 2,378 | 2,427 | 2,518 | 2,135 | 2,253 |
Other Equity | 3,276 | 3,364 | 3,558 | 3,446 | 3,532 |
Treasury Stock | 3 | 3 | 3 | 3 | 3 |
Total Shareholder's Equity | 9,752 | 9,864 | 10,084 | 9,585 | 9,814 |
Total Liabilities & Shareholder's Equity | 17,657 | 16,131 | 16,382 | 15,856 | 17,121 |
Total Common Equity | 9,752 | 9,864 | 10,084 | 9,585 | 9,814 |
Shares Outstanding | 594.30 | 597.40 | 597.40 | 598.30 | 603.20 |
Book Value Per Share | 16.41 | 16.51 | 16.88 | 16.02 | 16.27 |